CF PHARMTECH (02652) spent 395,000 Hong Kong dollars on February 2 to repurchase 11,000 shares.
Changfeng Pharmaceutical Industry (02652) announced that on February 2, 2026, it spent 395,000 Hong Kong dollars to repurchase 11,000 shares.
CF PHARMTECH (02652) announced on February 2, 2026 that it will spend 395,000 Hong Kong dollars to repurchase 11,000 shares.
Related Articles
Pagoda GP (02411) diluted its equity stake in Bai Guoyuan Commercial Management to 51.02%. The core management team increased its investment to expand into new business areas.
Tianli International Holdings (01773) director Luo Shi acquired an additional 1 million shares.
.png)
CHINA HEALTH (00673) issued a total of 40.638 million share options.
Pagoda GP (02411) diluted its equity stake in Bai Guoyuan Commercial Management to 51.02%. The core management team increased its investment to expand into new business areas.
Tianli International Holdings (01773) director Luo Shi acquired an additional 1 million shares.
CHINA HEALTH (00673) issued a total of 40.638 million share options.
RECOMMEND
Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026
Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026
2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026
